tbuckley/cabot-search huggingface dataset:
AB0179 Serum levels of interleukin-33 are associated with depressive symptoms in patients with primary sjÖgren’s syndrome
Authors: Z. Li, T. Fu, C. Dong, L. Li, Z. Gu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease which is more common among women than men. Extraglandular manifestations are commonly reported, including central nervous system (CNS) involvement such as headaches, cognitive deficits and mood disorder. Among mood disorder, depression is one of the most frequent disorders observed in patients with pSS. The pathogenesis of depression in pSS remains unclear. <h3>Objectives</h3> The aim of this study was to explore potential relationships between serum interleukin-33 (IL-33) levels and depressive symptoms in primary Sjögren's syndrome (pSS) patients. <h3>Methods</h3> We included 116 consecutive pSS patients (36 depression patients), and 71 (18 depression patients) age-and sex-matched healthy controls. The presence of depressive symptoms was determined through the Hospital Depression Scale (HDS). IL-33 levels were measured by enzyme-linked immunosorbent assay (ELASA) using commercial kits. <h3>Results</h3> There was no significant difference between pSS patients and controls. But, in pSS patients, the serum IL-33 levels were significantly lower in depression patients as compared to patients without depression [40.18 (IQR, 31.79–66.70) ng/ml vs. 39.95(IQR, 121.73)ng/ml; Z=−3.029, p=0.002]. A direct negative correlation between the score of HDAS-D and sera IL-33 levels (r=−0.805, p=0.000) in pSS was also observed. In logistic regression model using depression as the dependent variables, IL-33 is the independent predictors of depression in pSS (β=0.004; OR=1.004; 95% CI:1.998–0.011; p=0.170). Surprisingly, sera IL-33 levels were lower in depression patients with pSS compared to depression patients without pSS (Z=−2.316, p=0.021). <h3>Conclusions</h3> Conclusion: In pSS, IL-33 is the independent predictors of depressive disorders. Serum IL-33 levels are decreased in pSS patients with depressive symptoms, suggesting that IL-33 may play a unique role in depression with pSS. <h3>Acknowledgements</h3> This study was funded by the Chinese National Natural Science Foundation (Grant no. 81671616, and 81471603); Jiangsu Provincial Commission of Health and Family Planning Foundation (Grant no. H201317 and H201623); Science Foundation of Nantong City (Grant no. MS32015021, MS2201564, MS22016028 and MS22016019); Science and Technology Foundation of Nantong City (Grant no. HS2014071 and HS2016003). <h3>Disclosure of Interest</h3> None declared
Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma
Authors: Kosei Matsue, Yoshiaki Abe, Akihiro Kitadate, Daisuke Miura, Kentaro Narita, Hiroki Kobayashi, Masami Takeuchi, Naoko Enzan, Atsushi Tanaka, Kengo Takeuchi
Journal: Blood (2019)
AB0556 The diagnostic and predictive significance of nailfold video capillaroscopy in ctd patients with pulmonary arterial hypertension
Authors: B. Jiang, X. Xu, K. Zhou, C. Wang, L. Geng
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Pulmonary arterial hypertension (PAH) is a serious complication of connective tissue diseases (CTD), defined as an elevation in mean pulmonary artery pressure 25 mmHg at rest. The 1 year, 3 year survival rates of CTD-PAH are only 69% and 30% respectively. Therefore, to early prediction and diagnosis of PAH is very critical for prolonging survival of CTD patients. Nailfold video capillaroscopy (NVC), is an imaging technique for the study of microcirculation. Until now, capillary abnormalities in systemic sclerosis (SSc) are well documented, but rare study focus on the association between the abnormity of capillary with PAH in CTD patients. <h3>Objectives</h3> Through estimating the correlation of the abnormality of nailfold capillary with pulmonary arterial hypertension (PAH) and other organs injury to find out its importance on early diagnosis and prediction for PAH in the patients with connective tissue disease (CTD). <h3>Methods</h3> Nailfold video capillaroscopy (NVC) was performed using a videocapillaroscope to test the fingers capillaries of 123 hospitalised CTD patients with and without PAH. The parameters of NVC were estimated including: the inter, outer and top loop diameter, loop number, misshaped or giant capillaries, flowing speed, haemorrhage, erythrocyte aggregation, et al. The organ involvement like interstitial lung disease (ILD) and cardiovascular complications were also considered. Mann-Whitney test was used to estimate the difference. <h3>Results</h3> 1) The number of capillary loops in patients with SSc was much lower, but morphologic score, liquid score, and total score were all higher than other CTD patients (Tab). 2) The loop number was significantly decreased but abnormal scores of morphology, liquid, diameter, misshaped loop number, flowing speed, erythrocyte aggregation were increased in CTD-PAH patients especially in SLE-PAH compared with non-PAH patients (Fig). 3) ILD relates the abnormality of peripheral circulation such like capillary malformation, decreased loop number, diameter and blood flow, increased haemorrhage, but the influence of PAP may be larger than ILD. 4) Down-regulated loop number, increased morphology, liquid and total score, and abnormal diameter, malformation, erythrocyte aggregation were found in CTD patients with cardiovascular complications, especially in CTD-PAH patients and SLE patients. 5) Age doesn't directly influence the capillaries of CTD patients, but in young and middle age patients, the difference between PAH and non-PAH groups were more evident. <h3>Conclusions</h3> In all CTD, the capillaries in SSc patients are most severely damaged. The disease of capillaries in CTD patients correlates with PAH, ILD and cardiovascular complications. So, NVC could be a predictive detection method for PAH and cardiopulmonary disease in CTD patients. <h3>Disclosure of Interest</h3> None declared
Validation and reliability of a disease‐specific quality‐of‐life measure in patients with cutaneous lupus erythematosus
Authors: M.E. Ogunsanya, S.K. Cho, A. Hudson, B.F. Chong
Journal: British Journal of Dermatology (2019)

Cutaneous lupus erythematosus (CLE) is a potentially disfiguring, chronic autoimmune disease with variable skin manifestations, negatively affecting patients' quality of life (QoL). Patient-reported outcome (PRO) measures assessing QoL in patients with CLE have been generic or developed without input from patients.To demonstrate the reliability and validity of a disease-specific QoL measure for CLE - the cutaneous lupus erythematosus quality of life (CLEQoL).One hundred and one patients with CLE were recruited, and each patient was asked to complete the CLEQoL. Internal consistency was used as a measure of reliability. Validity was measured in two ways - structural validity via exploratory factor analysis and convergent validity via Spearman correlations between CLEQoL and the Short Form 36 (SF-36), visual analogue scales and clinical variables. Patient demographic and disease characteristics were collected.The mean ± SD age of patients with CLE was 48 ± 13 years, with discoid lupus (n = 72; 71.3%) being the most predominant CLE subtype. Patients were mostly female (n = 88; 87·1%) and African American/Black (n = 59; 58·4%). Internal consistency ranged from 0·67 to 0·97. Five domains (functioning, emotions, symptoms, body image/cosmetic effects and photosensitivity) were extracted with a total explained variance of 71·1%. CLEQoL-related domains correlated with SF-36 domains (r range -0·39 to -0·65).The CLEQoL was found to be a valid and reliable PRO measure for assessing QoL in patients with CLE. Demonstrating that the CLEQoL has strong psychometric properties is an important step towards the development of a disease-specific PRO measure that future clinical trials can use.
AB0591 Sle res ponder index (SRI) underestimates clinical response in musculoskeletal systemic lupus erythematosus
Authors: K. Mahmoud, A. Zayat, M.Y. Md Yusof, E. Hensor, P.G. Conaghan, P. Emery, E. Vital
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Musculoskeletal (MSK) manifestations are common in SLE. Many recent clinical trials were negative or had small benefits vs. placebo. SRI is a common primary endpoint but has not been independently validated. Ultrasound is an objective measure of synovitis validated in inflammatory arthritis. <h3>Objectives</h3> To compare the responsiveness of clinical outcome measures with ultrasound in MSK-SLE. <h3>Methods</h3> 20 SLE patients meeting SLICC 2012 criteria with inflammatory MSK symptoms were studied with clinical assessment (BILAG2004, SLEDAI-2K over 30 days, patient and physician VAS, symptomatic, tender and swollen joint counts in 28 joints) and MSK ultrasound (grey scale and power Doppler scores, number of abnormal joints) at 0, 2, and 4 weeks after 120 mg IM depomedrone. Change in each variable was measured using Wilcoxon matched pairs and effect sizes(r=Z/sqrt(2N) compared using Cohen (1988) criteria. Changes were compared for SRI-4 responders and non-responders. <h3>Results</h3> All patients were ANA positive, CCP negative and female. At baseline, 15/20 had clinical synovitis. The others had either ultrasound synovitis (GS in 18/20, PD in 17/20) or &gt;60 min EMS. 19/20 patients scored 4 points on SLEDAI for musculoskeletal involvement, BILAG scores were A in 7/20, B in 8/20, and C in 5/20. MSK-SLEDAI score improved in 9/20 at 4 weeks, MSK-BILAG improved in 16/20. For changes, see table 1. <h3>Conclusions</h3> In MSK-SLE, ultrasound was the variable most consistently sensitive to change. All commonly used clinical variables significantly improved by week 4 but there was variation in responsiveness between them. BILAG-2004 and physician VAS had similar responsiveness to ultrasound. SRI-4 underestimated response, with substantial objective improvements in synovitis in SRI-4 non-responders. Developing organ-specific outcome measures may improve the ability to measure treatment effects in SLE clinical trials. <h3>Disclosure of Interest</h3> None declared
Abstract 11730: Endogenous MAFbx Mediates Cardiac Rupture After Myocardial Infarction in Mice
Authors: Akio Chikata, Soichiro Usui, Shinichiro Takashima, Takeshi Kato, Hisayoshi Murai, Hiroshi Furusho, Shuichi Kaneko, Junichi Sadoshima, Masayuki Takamura
Journal: Circulation (2015)

Rationale: Muscle atrophy F-box (MAFbx/atrogin-1), an E3 ubiquitin ligase, plays a critical role in mediating skeletal muscle atrophy and induces proteasomal degradation in cardiomyocytes. Loss of function of MAFbx inhibits pressure overload-induced pathological cardiac hypertrophy, in part through stabilization of IκB. The role of MAFbx in regulating cardiac remodeling following myocardial infarction (MI) remains unclear. Objective: We investigated the role of MAFbx in regulating cardiac remodeling following MI. Methods and Results: Permanent coronary ligation of the left coronary artery was applied to MAFbx knockout (KO) and wild-type (WT) mice. Expression of MAFbx in WT mice was significantly increased in the risk area of the LV after MI. The mortality rate due to cardiac rupture following MI was significantly decreased in MAFbx KO mice compared to WT mice (25.3% in KO mice (n=61) vs. 47.7% in WT mice (n=59) P=0.03). There was no difference in the infarct sizes 3 days after MI or the number of TUNEL-positive cardiomyocytes between MAFbx KO mice and WT mice. DNA microarray analyses revealed that the gene expression pattern in hearts after MI demonstrated clear clusters for MAFbx KO and WT. Interestingly, upregulation of matrix metalloproteinase (MMP)-9, interleukin 1β, proinflammatory cytokines, and NLRP3, an inflammasone component, were attenuated in MAFbx KO mice. MMP-9 activity was also decreased in MAFbx KO in the risk area 3 days after MI compared to in WT mice. Flow cytometry revealed that myocardial leukocyte infiltration one day after MI was suppressed in MAFbx KO mice. Immunofluorescence double-labeling showed that expression of NLRP3 in both cardiomyocytes and non-cardiomyocyte cells was decreased in MAFbx KO mice. Conclusions: These results suggest that MAFbx plays an important role in the excessive inflammation, including leukocyte infiltration, inflammasome formation, and production of proinflammatory cytokines, following MI. Inhibition of MAFbx reduces mortality due to cardiac rupture after MI, in part through decreased MMP9 activity and leukocyte infiltration.
SAT0604 Secondary hemophagocytic syndrome: retrospective study according to the underlying disease
Authors: C.A. Egües Dubuc, J.A. Valero, A. De Diego, J.R. Furundarena, O. Maiz, L.M. López, J.J. Cancio, E. Uriarte, M.M. Yagüe, J. Calvo Alen, J.M. Belzunegui
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Secondary Hemophagocytic Syndrome (SHS) is associated with Hematoncologic (HO), Autoimmune (AI) diseases [such as Systemic Lupus Erythematosus (SLE) or Adult's Still Disease (ASD)] and in a lower frequency with Infections (Inf.) and Tumours (Tum.). <h3>Objectives</h3> Describe the demographic and underlying disorders during hospital admission of patients with SHS during the period December/2005-January/2018. <h3>Methods</h3> A retrospective search of patients diagnosed with SHS and bone marrow biopsy (B.M.O.) with hemophagocytosis was performed. Patients were grouped in: AI, HO, Inf, Tum. and SHS without cause (wc). The variables were: sex, age, diagnosis of the underlying disease, fever, organomegaly, laboratory findings, days of hospital stay, days from admission to B.M.O. and mortality. <h3>Results</h3> A total of 27 patients were found. table 1 shows the characteristics of the groups. AI &amp;x25A1;&amp;x25A1;diseases found were: 5 SLE, 2 ASD, 1 Rheumatoid Arthritis and 1 Sclerosing Disease Related to IgG4. The HOs were: 4 Myelodysplastic Syndrome, 3 Non-Hogkins Lymphomas, 2 Acute Leukemias, 1 Extranodal Lymphoma of Natural Killer Cells (NKC) and 1 Gastric Plasmocytoma. Inf. were: 1 infection of <i>Pneumocystis</i> in the recent diagnosis of HIV and Gastroenteritis by <i>Campylobacter yeyuni</i>. One Tum. in a patient with Glioblastoma multiforme who received temozolomide. During the follow-up no recurrence of SHS was observed. The sCD25 and cytolytic activity of the NKC were not done. <h3>Conclusions</h3> Patients with SHS to HO disease had a high mortality and a longer hospital stay compared to the rest of the groups. Practically all patients met all diagnostic criteria, the most frequent were fever, pancytopenia and hyperferritinemia. <h3>Disclosure of Interest</h3> None declared
AB0857 The burden of disease in patients with non-radiographic axial spondyloarthritis is not inferior to that of ankylosing spondylitis. the proof study
Authors: E. de Miguel Mendieta, S. Muñoz Fernández, C.A. Montilla Morales, J.M. Ruiz Martín, D. Reina Sanz, C. Aguilera Cros, M. Á. Belmonte Serrano, J.R. Noguera Pons, C.T. Barbazán Álvarez, M. Arranz, V. Díaz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> According to the 2009 ASAS classification criteria, a patient with chronic low back pain (CLBP) may be classified as axial spondyloarthritis (ax-SpA), with or without radiographic evidence of sacroiliitis, if at least one other SpA feature is present in the first case and positive HLA-B27 and at least two SpA features in the second one. There is concern about whether the classification ”axial non-radiographic spondyloarthritis” (ax-SpA-nr) includes patients with a mild disease that do not require treatment or special care by rheumatology. <h3>Objectives</h3> To compare disease burden between patients fulfilling criteria for AS and ax-SpA-nr. <h3>Methods</h3> Sub-analysis of Spanish patients from the PROOF study, an international prospective observational longitudinal study conducted in rheumatology clinics. All patients who attended rheumatology clinics due to CLBP (≥3 months, start &lt;45 years of age) from <sup>Jan 2015</sup> to ,<sup>Feb 2017</sup> not previously diagnosed were consecutively included. The ASAS criteria were applied to all, with centralised image reading. Patients with AS and ax-SpA-nr were compared. <h3>Results</h3> 192 patients with CLBP were included, of whom 151 (79%) met criteria of SpA-axe, 56 (43%) of AS and 74 (57%) of ax-SpA-nr (21 patients had X-ray missing or no central reading had been done so far). The table shows the description of patients with AS and ax-SpA-nr and their comparison. <h3>Conclusions</h3> Patients referred by CLBP to rheumatology clinics meeting ASAS criteria for AS or ax-SpA-nr differ little in terms of impact and disease activity; therefore, non-radiographic forms of ax-SpA require as much attention as classic AS. <h3>Acknowledgements</h3> The PROOF study was sponsored by AbbVie. AbbVie contributed to the study design, research, and interpretation of data, writing, reviewing, and approving the publication. The authors wish to thank Loreto Carmona (InMusc) for providing medical writing and editing services in the development of this abstract. The financial support for these services was provided by AbbVie. <h3>Disclosure of Interest</h3> E. de Miguel Mendieta Grant/research support from: Abbvie, S. Muñoz Fernández Grant/research support from: Abbvie, C. Montilla Morales Grant/research support from: Abbvie, J. Ruiz Martín Grant/research support from: Abbvie, D. Reina Sanz Grant/research support from: Abbvie, C. Aguilera Cros Grant/research support from: Abbvie, M. Á. Belmonte Serrano Grant/research support from: Abbvie, J. R. Noguera Pons Grant/research support from: Abbvie, C. Barbazán Álvarez Grant/research support from: Abbvie, M. Arranz Employee of: Abbvie, V. Díaz Employee of: Abbvie
AB0901 Vaspin and lipocalin2 levels in psoriatic arthritis
Authors: S. Colak, A. Omma, S. Can Sandikci, C. Yucel, T. Turhan
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Psoriathic athritis (PsA) is a type of spondiloarthropaties which is affiliated with psoriasis. Metabolic syndrome, diabetes mellitus and cardiovascular diseases are comorbid conditions associated with psoriatic arthritis. Adipokines are suggested to be playing proinflammatory or antiinflammatory roles in the proceeding of inflammatory situations. <h3>Objectives</h3> The aim of this study is to investigate the recently interested adipokines vaspin and lipocalin2 levels and their association with disease activity of patients diagnosed with psoriatic arthritis. <h3>Methods</h3> The study was conducted between <sup>October 2017</sup> and January 2018 at the Rheumatology Clinic of Ankara Numune Training and Research Hospital, Turkey. The vaspin and lipocalin2 levels of 50 PsA patients, diagnosed according to the Classification Criteria for Psoriatic Arthrtis (CASPAR), and 36 age-and sex-matched healthy subjects were analysed in current study. The disease activity was assessed by using Psoriasis Area Severity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Disease Activity Index and Disease Activity Index for Psoriatic Arthritis. Indexes were applied to the patients in order to evaluate the disease activity. <h3>Results</h3> No significant difference was found between groups with respect to age, sex and body mass index. There was significant difference between vaspin (p=0.001) and lipocalin2 (p=0.014) levels among the PsA patients and control groups. There was no significant difference between the groups in terms of disease activity (p&gt;0.05). <h3>Conclusions</h3> The results of this study points out the possible role of vaspin and lipocalin2 in PsA. In our knowledge, this is the first study comparing the vaspin and lipocalin2 levels of patients with PsA to healthy subjects and these findings may pioneer further studies investigating the usage of adipokines such as vaspin and lipocalin2 levels as biomarkers in the diagnose and disease course of PsA. <h3>Disclosure of Interest</h3> None declared
Molecular landmarks of tumor hypoxia across cancer types
Authors: Vinayak Bhandari, Christianne Hoey, Lydia Y. Liu, Emilie Lalonde, Jessica Ray, Julie Livingstone, Robert Lesurf, Yu-Jia Shiah, Tina Vujcic, Xiaoyong Huang, Shadrielle M. G. Espiritu, Lawrence E. Heisler, Fouad Yousif, Vincent Huang, Takafumi N. Yamaguchi, Cindy Q. Yao, Veronica Y. Sabelnykova, Michael Fraser, Melvin L. K. Chua, Theodorus van der Kwast, Stanley K. Liu, Paul C. Boutros, Robert G. Bristow
Journal: Nature Genetics (2019)
THU0566 Assessment of behavioural disorders in children with juvenile idiopathic arthritis
Authors: D. Dop, C.E. Niculescu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Juvenile Idiopathic Arthritis(JIA) is the most frequent paediatric rheumatologic disease which, because of its chronic, winding evolution, long-term treatment and dreadful complications, has a powerful impact on the somatic and psycho-social development of the children affected by it. <h3>Methods</h3> A number of 49 children with Juvenile Idiopathic Arthritis followed-up in the District Emergency University Hospital in Craiova and aged between 6 and 18, and a control group consisting in 49 healthy children of similar age and sex, were examined using the Child Behaviour Checklist (CBCL). <h3>Results</h3> Our results showed that 57.1% of the patients with JIA were classified as borderline and 6.12% as clinical behaviour, compared to the control group in which just 16.3% presented Internalising and Externalising problems. Thus, the majority of children with progressing forms of JIA presented social adjustment disorders, anxiety/depression, attention deficit, and 3 of them, males, presented verbal/physical aggressiveness and Rule-Breaking Behaviour. While among the patients with JIA it was mostly the feminine gender that presented behavioural disorders, in the control group all children with Internalising and Externalising problems were males. <h3>Conclusions</h3> Children with JIA must be carefully kept under observation for an early detection and treatment of behavioural deviations. Further studies are necessary, on large groups of patients, in order to identify the manner in which Juvenile Arthritis affects the patient and his or her family. <h3>Acknowledgements</h3> The authors declare that they have no conflict of interests. <h3>Disclosure of Interest</h3> None declared
Potential Benefits of Early Aggressive Treatment in Multiple Sclerosis
Authors: Ari J. Green
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal